Patent application EP17161008A (EP), filed 2017-03-15
Publication number: EP3219306A1
Title: COMPOSITION FOR PREVENTING AND TREATING NEUODEGENERATIVE DISEASES AD COGNITIVE DISORDERS
Abstract: [0001]    In one aspect thereof, the present invention relates to a composition for preventing or treating neurodegenerative diseases of the central nervous system or ocular diseases or cognitive disorders, said composition comprising a combination of citicoline and homotaurine in a therapeutically effective amount. The composition may be in the form of drug, nutraceutical, food supplement, food or dietary supplement.
IPC codes: A23L  33/    10            A I
A61K  31/   185            A I
A61K  31/   353            A I
A61K  31/   355            A I
A61K  31/  7068            A I
A61K   9/    00            A I
A61P  25/    28            A I
A61P  27/    02            A I
A61P  27/    06            A I
A23L  33/    15            A I
A61K   9/    24            A I
A61K   9/    28            A I
Claims: number: 1
text: A composition comprising a combination of citicoline or a pharmaceutically acceptable salt thereof and homotaurine and a physiologically acceptable carrier and/or excipient.
number: 2
text: A composition according to claim 1, further comprising a substance provided with a cellular antioxidant activity.
number: 3
text: A composition according to claim 1 or 2, wherein said substance provided with a cellular antioxidant activity is selected from tocopherols α, β, γ or δ, tocotrienols α, β, γ or δ.
number: 4
text: A composition according to claim 3, wherein said tocopherol is α-tocopherol or vitamin E.
number: 5
text: A composition according to any one of claims 1 to 3, characterized in that it is in the form for oral administration.
number: 6
text: A composition according to any one of claims 1 to 5, characterized in that it is a dietary supplement, a nutraceutical, a drug or a food supplement.
number: 7
text: A composition according to any one of claims 1-6, characterized in that it is in the form of a tablet.
number: 8
text: A composition according to claim 7, wherein said tablet is gastro-resistant.
number: 9
text: A composition according to any one of claims 1-9 for use in the prevention or treatment of a neurodegenerative disease and/or a reversible cognitive disorder, a vascular disease and/or a neurodegenerative ocular disease.
number: 10
text: A composition for use according to claim 9, wherein said cognitive disorder is senile dementia, vascular cognitive impairment, Alzheimer's disease, amnestic deficits, and wherein said neurodegenerative ocular disease is glaucoma or macular degeneration.
Office action: search_report, dated 2017-09-20
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: - COTRONEO AM; CASTAGNA A; PUTIGNANO S; LACAVA R; FANT6 F; MONTELEONE F; ROCCA F; MALARA A; GARERI P: "Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study", CLIN INTERV AGING., vol. 8, 2013, pages 131 - 7
ref_type: npl
severity: background
ref_id: - GRUBER SA; SAGAR KA; DAHLGREN MK; GONENG A; CONN NA; WINER JP; PENETAR D; LUKAS SE.: "Citicoline Treatment Improves Measures of Impulsivity and Task Performance in Chronic Marijuana Smokers: A Pilot BOLD fMRI Study", INT J NEUROL NEUROTHER., vol. 2, no. 3, 30 September 2015 (2015-09-30), pages 1 - 8
ref_type: npl
severity: background
ref_id: - MCGLADE E; AGOSTON AM; DIMUZIO J; KIZAKI M; NAKAZAKI E; KAMIYA T; YURGELUN-TODD D: "The Effect of Citicoline Supplementation on Motor Speed and Attention in Adolescent Males", J ATTEN DISORD., 15 July 2015 (2015-07-15)
ref_type: npl
severity: background
ref_id: - KNOTT V; DE LA SALLE S; SMITH D; CHOUEIRY J; IMPEY D; SMITH M; BEAUDRY E; SAGHIR S; LLIVITSKY V; LABELLE A: "Effects of acute CDP-choline treatment on resting state brain oscillations in healthy volunteers", NEUROSCI LETT., vol. 591, 30 March 2015 (2015-03-30), pages 121 - 5, XP029204562, DOI: doi:10.1016/j.neulet.2015.02.032
ref_type: npl
severity: background
ref_id: - ALVAREZ-SABIN J; ORTEGA G; JACAS C; SANTAMARINA E; MAISTERRA 0; RIBO M; MOLINA C; QUINTANA M; ROMAN GC: "Long-term treatment with citicoline may improve poststroke vascular cognitive impairment", CEREBROVASC DIS., vol. 35, no. 2, 2013, pages 146 - 54
ref_type: npl
severity: background
ref_id: - ZAFONTE RD; BAGIELLA E; ANSEL BM; NOVACK TA; FRIEDEWALD WT; HESDORFFER DC; TIMMONS SD; JALLO J; EISENBERG H; HART T: "Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT)", JAMA, vol. 308, no. 19, 21 November 2012 (2012-11-21), pages 1993 - 2000
ref_type: npl
severity: background
ref_id: - ALVAREZ-SABM J; ROMAN GC: "Citicoline in vascular cognitive impairment and vascular dementia after stroke", STROKE, vol. 42, no. 1, January 2011 (2011-01-01), pages S40 - 3
ref_type: npl
severity: background
ref_id: - GARCFA-COBOS R; FRANK-GARCFA A; GUTIERREZ-FERNANDEZ M; DFEZ-TEJEDOR E: "Citicoline, use in cognitive decline: vascular and degenerative", J NEUROL SCI., vol. 299, no. 1-2, 15 December 2010 (2010-12-15), pages 188 - 92, XP027526285
ref_type: npl
severity: background
ref_id: - GREENBERG SM; ROSAND J; SCHNEIDER AT ET AL.: "A phase 2 study of tramiprosate for cerebral amyloid angiopathy", ALZHEIMER DIS ASSOC DISORD, vol. 20, 2006, pages 269 - 74
ref_type: npl
severity: background
ref_id: - SAUMIER D; AISEN PS; GAUTHIER S ET AL.: "Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (tramiprosate) experience", J NUTR HEALTH AGING, vol. 13, 2009, pages 370 - 2
ref_type: npl
severity: background
ref_id: - AISEN PS; GAUTHIER S; FERRIS SH ET AL.: "Tramiprosate in mild-tomoderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)", ARCH MED SCI, vol. 1, 2011, pages 102 - 11
ref_type: npl
severity: background
ref_id: - SAUMIER D; DUONG A; HAINE D; GARCEAU D; SAMPALIS J.: "Domainspecific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study", J NUTR HEALTH AGING, vol. 13, 2009, pages 808 - 12
ref_type: npl
severity: background
ref_id: - SPALLETTA G; CRAVELLO L; GIANNI W; PIRAS F ET AL.: "Homotaurine Effects on Hippocampal Volume Loss and Episodic Memory in Amnestic Mild Cognitive Impairment", J. ALZHEIMERS DIS., vol. 50, no. 3, 2016, pages 807 - 16
ref_type: npl
severity: background
ref_id: - GERVAIS F; PAQUETTE J; MORISSETTE C ET AL.: "Targeting A? peptide with tramiprosate for the treatment of brain amyloidosis", NEUROBIOL AGING, vol. 28, 2007, pages 537 - 47, XP005901142, DOI: doi:10.1016/j.neurobiolaging.2006.02.015
ref_type: npl
severity: background
ref_id: - TALLARIDA RJ: "Drug Synergism: its detection and applications", J PHARMACOLEXPTHER., vol. 298, no. 3, September 2001 (2001-09-01), pages 865 - 72, XP007918154
ref_type: npl
severity: background
ref_id: - CAO, G. ET AL., FREE RADIC. BIOL. MED., vol. 14, no. 3, 1993, pages 303 - 11
ref_type: npl
severity: background
ref_id: - GHISELLI, A.; ET AL., FREE RADIC. BIOL. MED., vol. 18, no. 1, 1995, pages 29 - 36
ref_type: npl
severity: background
ref_id: - WAYNER, D. D ET AL., FEBS LETT., vol. 187, no. 1, 1985, pages 33 - 7
ref_type: npl
severity: background
ref_id: US6015835A
ref_type: patent
severity: background
ref_id: WO2007049098A2
ref_type: patent
severity: background
ref_id: US2010130537A1
ref_type: patent
severity: background
ref_id: US2012316128A1
ref_type: patent
severity: background
ref_id: US2003114415A1
ref_type: patent
severity: background
ref_id: - JUDES POIRIER ET AL: "Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress", CURRENT PHARMACOGENOMICS AND PERSONALIZED MEDICINE, 1 March 2008 (2008-03-01), pages 63 - 76, XP055315182, Retrieved from the Internet <URL:http://adgen.myasustor.com/index_htm_files/Current%20Pharmacogen%20Pers%20Med%206_63.pdf> [retrieved on 20161028], DOI: 10.2174/187569208784017494
ref_type: npl
severity: background
ref_id: US6015835
ref_type: patent
severity: novelty_destroying
ref_id: US2003114415
ref_type: patent
severity: background
ref_id: WO2007049098
ref_type: patent
severity: obviousness
ref_id: US2010130537
ref_type: patent
severity: obviousness
ref_id: US2012316128
ref_type: patent
severity: background
ref_id: - Judes Poirier ET AL, "Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress", Current Pharmacogenomics and Personalized Medicine, doi:10.2174/187569208784017494, (20080301), pages 63 - 76, URL: http://adgen.myasustor.com/index_htm_files/Current%20Pharmacogen%20Pers%20Med%206_63.pdf, (20161028), XP055315182 [A] 1-10 * page  71, column  l, paragraph  3 * * page  71, column  l, paragraph  4 *
ref_type: npl
severity: background
Final disposition: pending (2017-09-20)